Krystal Biotech, Inc. (KRYS)
NASDAQ
350.88
+17.03 (+5.10%)
Closed
Sep 22, 2026
Day's Range
334.31353.75
52 wk Range
158.08382.54
Financial Statements - KRYS - Krystal Biotech, Inc.
Revenue
389.13M▲ 33.9%
Net Income
204.83M▲ 129.7%Net Margin 52.6%
EBITDA
167.84M▲ 13.9%
Free Cash Flow
188.91M▲ 58.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 389.13M | 290.51M | 50.69M | 0 | 0 | 0 |
| Cost of Goods | 23.04M | 20.06M | 3.09M | 0 | 0 | - |
| Gross Profit | 366.08M | 270.45M | 47.60M | 0 | 0 | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 161.29M | 103.19M | -97.22M | -120.19M | -68.27M | -32.99M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | -37.50M | 87.50M | -25M | - | - |
| Pre Tax Income | 189.47M | 95.35M | 12.89M | -139.97M | -69.57M | -32.16M |
| Income Tax | -15.36M | 6.19M | 1.96M | 0 | 0 | - |
| Net Income | 204.83M | 89.15M | 10.93M | -139.97M | -69.57M | -32.16M |
| EPS Basic | 7.08 | 3.12 | 0.4 | -5.49 | -3.13 | -1.71 |
| EPS Diluted | 6.84 | 3 | 0.39 | -5.49 | -3.13 | -1.71 |
| Basic Shares Outstanding | 28.94M | 28.59M | 27.15M | 25.49M | 22.19M | 18.78M |
| Diluted Shares Outstanding | 28.94M | 28.59M | 27.15M | 25.49M | 22.19M | 18.78M |
| Ebit | 161.29M | 103.19M | 12.89M | -139.97M | -68.07M | -32.16M |
| Ebitda | 167.84M | 147.40M | -69.59M | -112.33M | -66.22M | -30.31M |
| Net Income Continuous Operations | 204.83M | 89.15M | 10.93M | -139.97M | -69.57M | -32.16M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
